Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Multiple Cancer Types
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care. The study will last up to approximately 2 years.
Colon, Gastrointestinal, Lung, Miscellaneous, Non Small Cell, Phase I, Rectal